Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model

Cardiovasc Res. 2005 Dec 1;68(3):493-501. doi: 10.1016/j.cardiores.2005.06.026. Epub 2005 Aug 15.

Abstract

Objective: To determine the influence of IL-1 on the arterial response to experimental injury in porcine models of percutaneous coronary intervention (PCI).

Methods: An intravenous (i.v.) bolus of 0.5 mg/kg followed by a subcutaneous (s.c.) infusion of 2 mg/kg/24 h of human IL-1 receptor antagonist (IL-1ra) inhibited neutrophil recruitment in response to intradermal IL-1. Using this dose regimen, five groups of pigs were studied: Group 1, oversized balloon angioplasty of 2 coronary vessels (14-day infusion, 28th day sacrifice and analysis); Groups 2, 3, 4, and 5, oversized stenting of 2 coronary vessels (Group 2: 14-day infusion, 28th day analysis; Group 3: 14-day infusion, 14th day analysis; Group 4: 28-day infusion, 28th day analysis; Group 5: 28-day infusion, 90th day analysis). Neointimal area was quantified by standard means.

Results: In Group 1, IL-1ra resulted in a 23% decrease in neointimal area (p=0.04); in Group 2, a 34% increase (p=0.001); in Group 3, a 38% decrease (p<0.0001); in Group 4, a 34% decrease (p=0.0004); and in Group 5, a 41% decrease (p=0.00001).

Conclusions: IL-1ra was associated with a sustained, significant reduction in neointima after vessel wall injury as long as it is given for the duration of the stimulation of the IL-1 system, in this case at least 28 days. This suggests that therapies based on the antagonism of IL-1 may modulate the coronary artery response to injury.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects*
  • Animals
  • Coronary Restenosis / metabolism
  • Coronary Restenosis / pathology
  • Coronary Restenosis / prevention & control*
  • Coronary Stenosis / metabolism
  • Coronary Stenosis / therapy
  • Coronary Vessels / injuries*
  • Coronary Vessels / metabolism*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / metabolism
  • Male
  • Models, Animal
  • Random Allocation
  • Sialoglycoproteins / metabolism
  • Sialoglycoproteins / therapeutic use*
  • Swine
  • Time Factors
  • Tunica Intima / drug effects
  • Tunica Intima / pathology

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Sialoglycoproteins